B cell targeted therapies in inflammatory autoimmune disease of the central nervous system
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F23%3A73620092" target="_blank" >RIV/61989592:15110/23:73620092 - isvavai.cz</a>
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129906/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129906/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fimmu.2023.1129906" target="_blank" >10.3389/fimmu.2023.1129906</a>
Alternative languages
Result language
angličtina
Original language name
B cell targeted therapies in inflammatory autoimmune disease of the central nervous system
Original language description
Cumulative evidence along several lines indicates that B cells play an important role in the pathological course of multiple sclerosis (MS), neuromyelitisoptica spectrum disorders (NMOSD) and related CNS diseases. This has prompted extensive research in exploring the utility of targeting B cells to contain disease activity in these disorders. In this review, we first recapitulate the development of B cells from their origin in the bone marrow to their migration to the periphery, including the expression of therapy-relevant surface immunoglobulin isotypes. Not only the ability of B cells to produce cytokines and immunoglobulins seems to be essential in driving neuroinflammation, but also their regulatory functions strongly impact pathobiology. We then critically assess studies of B cell depleting therapies, including CD20 and CD19 targeting monoclonal antibodies, as well as the new class of B cell modulating substances, Bruton ' s tyrosinekinase (BTK) inhibitors, in MS, NMOSD and MOGAD.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Immunology
ISSN
1664-3224
e-ISSN
—
Volume of the periodical
14
Issue of the periodical within the volume
September 2023
Country of publishing house
CH - SWITZERLAND
Number of pages
14
Pages from-to
1129906
UT code for WoS article
000954816000001
EID of the result in the Scopus database
2-s2.0-85150706254